URGN

UroGen Pharma Ltd. (URGN) | Rumor.io

UroGen Pharma

URGN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,117

Bullish sentiment (50-day avg)98%

Price to earnings ratio-12.8

Market capitalization2B

Earnings per share-1.97

Dividend yield (TTM)—

Revenue (annual)109.8M

Net income (annual)-153.5M

Social

What share of all stock conversation is about URGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 5

UroGen Pharma's Q2 2026 revenue was $72.46 million, a 199% year-over-year increase, driven by strong sales of its ZUSDURI product, which generated $50.4 million in revenue, a 73% quarter-over-quarter growth.
The company reported a net loss of $14.4 million, but the earnings call did not provide formal full-year guidance for ZUSDURI due to management's desire to focus on the product's continued commercial launches.
UroGen's stock price surged 18% following the earnings report, with some analysts predicting further growth, citing the company's rerating potential and the strong performance of its ZUSDURI product.

Generated by AI

Sentiment

Of the messages about URGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +3.23	92.1% +6.3
Bearish	0%	0% 0	0% -3.23	7.9% -6.3

Bullish· Nov 6

$URGN is expected to have a strong year in 2026, with potential for significant growth.
UroGen Pharma's recent earnings report showed positive momentum for ZUSDURI sales, with the FDA agreeing to support a New Drug Application for UGN-103, a treatment for recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer.
The company's pipeline, including UGN-103, has the potential to deliver meaningful patient benefits, with two U.S. patents expiring in December 2041 providing protection for the therapy.

Bearish· Jun 13

The company's product launch may be slow due to a smaller-than-expected target market and a lack of direct comparison with competitors.
The US FDA's decision to reject the company's therapy may have a negative impact on the stock, as it avoids surgery and has fewer side effects.
The stock's price may be artificially inflated by institutions holding calls and waiting for a catalyst to sell, rather than by fundamental value.

Generated by AI

Topics

Of the messages about URGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	67.31%	73.8%
Technical Analysis	—	—	26.92%	9.21%
Earnings	—	—	0%	9.44%
Analysts	—	—	5.77%	6.61%
Controversies	—	—	0%	0.31%
Macro	—	—	0%	0.63%

Earnings· Mar 15

UroGen Pharma Ltd. ($URGN) missed Q4 2017 earnings estimates by $0.12.
The company's earnings call is available live at 08:30 AM, with on-demand access after.
$URGN's Q4 2017 earnings missed loss estimates by $0.12.

Analysts· Jun 13

Guggenheim raised UroGen Pharma's price target to $30 from $15, citing $800M US sales at peak in 2030 for Zusduri/UGN-102.
Scotiabank raised UroGen Pharma's price target to $47 from $23, maintaining a Sector Outperform rating and citing a peak ZUSDURI market opportunity of about $1B in low-grade NMIBC alone.
Oppenheimer raised UroGen Pharma's price target to $31 from $10, reiterating an Outperform rating and citing $1B in sales over time, advising to take advantage of near-term weakness.

Announcements· Jun 13

UroGen Pharma's $URGN ZUSDURI has received FDA approval for recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC), with a 78% complete response rate at 3 months in the Phase 3 ENVISION trial.
Analysts have upgraded their price targets for $URGN, with Guggenheim raising its target to $30 and Scotiabank to $47, citing potential sales of $800M and $1B, respectively, for Zusduri/UGN-102.
UroGen Pharma has a cash reserve of $195 million and plans to commercialize ZUSDURI starting July 1, 2025, with multiple analysts expecting the company to reach $1B in sales over time.

Generated by AI

Community

Of the messages about URGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	63.57%	61.11%
Newcomers	0%	0%	36.43%	38.89%

Regulars· Aug 5

UroGen Pharma reported a blowout quarter with revenue of $72.46m, a 199% YoY increase, and EBIT of $0.11m, beating expectations.
The stock is up 18% following the earnings report, with key takeaways from the call including no formal full-year guidance for Zusduri and a strong QoQ performance.
UroGen's Zusduri revenue reached $50.4m, a 73% QoQ increase, with 1,444 activated care sites and 452 unique prescribers, and the company is on track to submit its NDA for UGN-103 in Q3 2026.

Newcomers· Jul 16

New investors are focusing on the tight pivot in URGN's stock price, indicating a potential turning point in the company's momentum.
The rise of URGN as a biotech stock is being discussed, with some newcomers highlighting its potential for future growth.
Some users are expressing concerns about the stock's volatility, citing the tight pivot as a reason to be cautious when considering an investment in URGN.

Generated by AI

UroGen Pharma has seen its share price move sharply over recent years, which naturally puts a spotlight on whether the current valuation lines up with the sales the business is generating. For anyone looking at the stock today, the core issue is how much of that move can be explained by the company’s revenue base rather than by sentiment alone. Over the past 3 years the stock has delivered a gain of 188.5%, which raises the question of how closely that share price climb tracks the growth in...

5d agoYahoo Finance

Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?

UroGen Pharma (NASDAQ:URGN) operates as a specialized oncology and urology therapeutics company anchored by proprietary sustained-release technology platforms. By developing localized drug delivery systems designed to retain therapeutics in targeted tissue sites for extended periods, the company addresses the significant clinical limitations of systemic toxicity and rapid clearance common in traditional cancer treatments. Its underlying […]

6d agoYahoo Finance

Also Discussed

Investors talking about URGN also mention

#	Name	Attention
1	Dianthus Therapeutics Inc.DNTH	0%0
2	Travere Therapeutics Inc.TVTX	0%0
3	SWTX - SpringWorks Therapeutics, Inc.	——
4	VRNA - Verona Pharma plc	——
5	Nuvation Bio Inc.NUVB	0%0
6	DAWN - Day One Biopharmaceuticals, Inc.	——
7	Tango Therapeutics Inc.TNGX	0%new
8	KALV - KalVista Pharmaceuticals, Inc.	——
9	OPTN - OptiNose, Inc.	——
10	SCPH - scPharmaceuticals Inc.	——

UroGen Pharma Ltd.

Healthcare
Biotechnology

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers. The company’s current portfolio centers on its proprietary RTGel reverse-thermal hydrogel platform, which is designed to support localized drug delivery and prolonged contact with urinary tract tissue. Its marketed therapies and pipeline are built around non-surgical, organ-sparing approaches for conditions such as upper tract urothelial cancer and non-muscle invasive bladder cancer. UroGen Pharma Ltd. also advances additional investigational candidates aimed at expanding options in uro-oncology, combining drug formulation expertise with targeted delivery technologies. Headquartered in Princeton, New Jersey, with operations in Israel, the company plays a specialized role in the urology and oncology markets by focusing on treatments tailored to diseases of the urinary tract.

Website

Location

400 Alexander Park Drive

Princeton, NJ, 08540

United States

Social

What share of all stock conversation is about URGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 5

UroGen Pharma's Q2 2026 revenue was $72.46 million, a 199% year-over-year increase, driven by strong sales of its ZUSDURI product, which generated $50.4 million in revenue, a 73% quarter-over-quarter growth.
The company reported a net loss of $14.4 million, but the earnings call did not provide formal full-year guidance for ZUSDURI due to management's desire to focus on the product's continued commercial launches.
UroGen's stock price surged 18% following the earnings report, with some analysts predicting further growth, citing the company's rerating potential and the strong performance of its ZUSDURI product.

Generated by AI

Sentiment

Of the messages about URGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% +3.23	92.1% +6.3
Bearish	0%	0% 0	0% -3.23	7.9% -6.3

Bullish· Nov 6

$URGN is expected to have a strong year in 2026, with potential for significant growth.
UroGen Pharma's recent earnings report showed positive momentum for ZUSDURI sales, with the FDA agreeing to support a New Drug Application for UGN-103, a treatment for recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer.
The company's pipeline, including UGN-103, has the potential to deliver meaningful patient benefits, with two U.S. patents expiring in December 2041 providing protection for the therapy.

Bearish· Jun 13

The company's product launch may be slow due to a smaller-than-expected target market and a lack of direct comparison with competitors.
The US FDA's decision to reject the company's therapy may have a negative impact on the stock, as it avoids surgery and has fewer side effects.
The stock's price may be artificially inflated by institutions holding calls and waiting for a catalyst to sell, rather than by fundamental value.

Generated by AI

Topics

Of the messages about URGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	67.31%	73.8%
Technical Analysis	—	—	26.92%	9.21%
Earnings	—	—	0%	9.44%
Analysts	—	—	5.77%	6.61%
Controversies	—	—	0%	0.31%
Macro	—	—	0%	0.63%

Earnings· Mar 15

UroGen Pharma Ltd. ($URGN) missed Q4 2017 earnings estimates by $0.12.
The company's earnings call is available live at 08:30 AM, with on-demand access after.
$URGN's Q4 2017 earnings missed loss estimates by $0.12.

Analysts· Jun 13

Guggenheim raised UroGen Pharma's price target to $30 from $15, citing $800M US sales at peak in 2030 for Zusduri/UGN-102.
Scotiabank raised UroGen Pharma's price target to $47 from $23, maintaining a Sector Outperform rating and citing a peak ZUSDURI market opportunity of about $1B in low-grade NMIBC alone.
Oppenheimer raised UroGen Pharma's price target to $31 from $10, reiterating an Outperform rating and citing $1B in sales over time, advising to take advantage of near-term weakness.

Announcements· Jun 13

UroGen Pharma's $URGN ZUSDURI has received FDA approval for recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC), with a 78% complete response rate at 3 months in the Phase 3 ENVISION trial.
Analysts have upgraded their price targets for $URGN, with Guggenheim raising its target to $30 and Scotiabank to $47, citing potential sales of $800M and $1B, respectively, for Zusduri/UGN-102.
UroGen Pharma has a cash reserve of $195 million and plans to commercialize ZUSDURI starting July 1, 2025, with multiple analysts expecting the company to reach $1B in sales over time.

Generated by AI

Community

Of the messages about URGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	63.57%	61.11%
Newcomers	0%	0%	36.43%	38.89%

Regulars· Aug 5

UroGen Pharma reported a blowout quarter with revenue of $72.46m, a 199% YoY increase, and EBIT of $0.11m, beating expectations.
The stock is up 18% following the earnings report, with key takeaways from the call including no formal full-year guidance for Zusduri and a strong QoQ performance.
UroGen's Zusduri revenue reached $50.4m, a 73% QoQ increase, with 1,444 activated care sites and 452 unique prescribers, and the company is on track to submit its NDA for UGN-103 in Q3 2026.

Newcomers· Jul 16

New investors are focusing on the tight pivot in URGN's stock price, indicating a potential turning point in the company's momentum.
The rise of URGN as a biotech stock is being discussed, with some newcomers highlighting its potential for future growth.
Some users are expressing concerns about the stock's volatility, citing the tight pivot as a reason to be cautious when considering an investment in URGN.

Generated by AI

UroGen Pharma

Social

Aug 5

Bullish· Nov 6

Bearish· Jun 13

Earnings· Mar 15

Analysts· Jun 13

Announcements· Jun 13

Regulars· Aug 5

Newcomers· Jul 16

UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base

Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?

UroGen at H.C. Wainwright conference: Zusduri launch gains speed

Portfolio Change Alert: Adding UroGen Pharma To Model Portfolio (NASDAQ:URGN)

UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction

Jefferies reiterates UroGen Pharma stock rating on rival drug data

Also Discussed

UroGen Pharma Ltd.

Company Information

Location

UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base

Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?

UroGen at H.C. Wainwright conference: Zusduri launch gains speed

Portfolio Change Alert: Adding UroGen Pharma To Model Portfolio (NASDAQ:URGN)

UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction

Jefferies reiterates UroGen Pharma stock rating on rival drug data

Also Discussed

Social

Aug 5

Bullish· Nov 6

Bearish· Jun 13

Earnings· Mar 15

Analysts· Jun 13

Announcements· Jun 13

Regulars· Aug 5

Newcomers· Jul 16